A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513305-32-00

Acronym

M1095-PPP-201

Enrollment

Registered

2024-09-20

Start date

2024-10-29

Completion date

2025-09-30

Last updated

2025-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palmoplantar Pustulosis

Brief summary

Percent change from baseline in PPPASI score at Week 16

Interventions

DRUGSonelokimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent change from baseline in PPPASI score at Week 16	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026